** Shares of drugmaker Y-mAbs Therapeutics fall 6.6% to $6.90
** YMAB says it is creating two business units, one to accelerate the clinical development of its radiopharmaceuticals unit and another to optimize the commercial growth of Danyelza
** Company's radiopharmaceuticals unit develops targeted cancer therapies by delivering high doses of radiation directly to tumors while minimizing exposure to healthy tissues
** Danyelza is an FDA-approved cancer therapy for the treatment of relapsed or refractory neuroblastoma in the bone or bone marrow
** YMAB also plans to lay off 13% of its employees, depending on whether a portion of the impacted employees accepts newly created positions
** Company had 100 full-time employees as of Dec. 31, 2023 - SEC filing
** YMAB says it plans to move some roles from Denmark to the U.S.
** YMAB gained ~14% in 2024
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.